Recipient Evaluation

Gast KK, Puderbach MU, Rodriguez I et al. Distribution of ventilation in lung transplant recipients evaluation by dynamic He-MRI with lung motion correction. Invest Radiol 2003 38 341-348. 

Kirklin JK, Young JB, McGiffin DC (2002a) Recipient evaluation and selection. In Kirklin JK, Young JB, McGiffin DC (eds) Heart transplantation. Churchill Livingstone, New York, pp 198-231... 

Boraschi P, Donati F, Gigoni R et al (2004) Ischemic-type biliary lesions in liver transplant recipients evaluation with magnetic resonance cholangiography. Transplant Proc 36 2744-2747... 

Lewis R, Canafax D, Pettit K, et al. Use of Markov model for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients. Transpl Proc 1996 28 2214-17. 

Review any available diagnostic and laboratory data to evaluate the function of the allograft and the health of the recipient. 

Several lines of investigation assert to the inability of canal ine to function as an effective ornithine antagonist. Ornithine interaction with canaline has been evaluated with the ornithine carbamoyl transferase (EC 2.1.3.3) of human liver. Neither canal ine nor ornithine inhibited this enzyme when the other member of this set served as the carbamoyl group recipient (29). The ornithine antagonist, 2,4-diaminobutyric acid drastically reduced urea production in the rat this reflected curtailment of the ornithine carbamoyl transferase-mediated conversion of ornithine to citrulline. Yet, canaline had no such effect on urea formation in this mammal (30). 

One final comment. When you read a paper or listen to a lecture offered by a researcher of impeccable qualifications, take a moment to look about you to see who is along side you in the audience that is being addressed. Who else is reading his paper Who else is hearing his lecture How might the presentation be tailored to fit the interests of the recipients The identification and recognition of your neighbors should play a role in your evaluation and acceptance of the presentation. 

Decisions cannot involve merely risk benefit evaluations should include the nature, extent, and recipient of the benefits. It is often necessary to accept risks when the benefits warrant the risk, but risks imposed on persons who gain no benefits are generally not acceptable. The committee concluded the following ... 

In a retrospective study that included 163 consecutive recipients of allogenic hemopoietic stem cell transplants with invasive fungal infections, the possible role of glucocorticoid therapy was evaluated. The administration of high-dose glucocorticoids (2 mg/kg/day or more) was associated with an increased risk of mold infection (HR = 4.0, 95% Cl = 1.7, 9.6) and an increased risk of mold infection-related death (1 year survival 11% compared with 44% when patients took doses less than 2 mg/ kg/day) (343). 

At present, we can induce CML in mice with high efficiency, shown by 100% induction of CML in mice (14). The same CML disease could be induced in most of the inbred mouse strain including C57BL/6, BALB/c, and viable gene knockout mice strains (15). Because all recipients develop CML with a short latency (about 3 weeks), this provides an excellent model for evaluating therapeutic agents for CML treatment (15). As CML is derived from the hematopoietic stem cells which harbor BCR-ABL oncogene, CML leukemia stem cells can also be studied in this model (15). In conclusion, this retroviral model system pro-... 

---